Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults
- Conditions
- Human Influenza
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2017-10-12
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 254648
- Registration Number
- NCT02600585
- Locations
- 🇺🇸
Kaiser Permanente Vaccine Study Center, Oakland, California, United States
Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older
- Conditions
- Influenza
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 407
- Registration Number
- NCT02464163
- Locations
- 🇺🇸
Coastal Clinical Research, Mobile, Alabama, United States
🇺🇸Avail Clinical Research, DeLand, Florida, United States
🇺🇸Meridian Clinical Research, Omaha, Nebraska, United States
Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age
- Conditions
- Influenza
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 1350
- Registration Number
- NCT02290509
- Locations
- 🇺🇸
Benchmark Research - Sacramento, Sacramento, California, United States
🇺🇸Clinical Research of South Florida, Coral Gables, Florida, United States
🇺🇸Meridian Clinical Research, Omaha, Nebraska, United States
Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age
- Conditions
- Influenza
- First Posted Date
- 2014-11-07
- Last Posted Date
- 2017-10-27
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 9003
- Registration Number
- NCT02285998
- Locations
- 🇺🇸
Coastal Clinical Research, Mobile, Alabama, United States
🇺🇸Clinical Research Consortium Arizona, Tempe, Arizona, United States
🇺🇸Baptist Health Center for Clinical Research, Little Rock, Arkansas, United States
Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)
- Conditions
- Influenza
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Protein Sciences Corporation
- Target Recruit Count
- 219
- Registration Number
- NCT01959945
- Locations
- 🇺🇸
Maine Research Associates, LLC, Auburn, Maine, United States
- Prev
- 1
- 2
- 3
- Next